

organized by:



Melanoma Bridge



Naples,
Royal Continental Hotel
December 5th - 8th, 2013

under the auspices:



ORGANIZED BY



Fondazione Melanoma Onlus



**Istituto Nazionale Tumori - IRCCS
"Fondazione G.Pascale"**



**Sidra Medical and Research
Center**



**Society for Immunotherapy of
Cancer**

UNDER THE AUSPICES

Associazione Italiana di
Oncologia Medica




European Society for Medical
Oncology



Intergruppo Melanoma Italiano



Naples, Royal Continental Hotel
December 5th - 8th, 2013



WELCOME TO NAPLES

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma, more than 40 international faculty members are now joining "Melanoma Bridge 2013". After the first meeting "Melanoma Research: a bridge Naples-USA" (Naples, December 6-7th 2010), the second edition "Melanoma Research: a bridge from Naples to the World" (Naples, December 5-6th 2011), and the third "Melanoma Bridge 2012", the 2013 Congress will take place from December 5th to 8th in Naples, jointly organized by Istituto Nazionale Tumori Fondazione "G. Pascale" and Fondazione Melanoma Onlus, together with the Society for ImmunoTherapy of Cancer (SITC) and Sidra Medical and Research Center (Doha, Qatar).

Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (Sidra Center, Doha, Qatar), and Nicola Mozzillo (INT, Naples, Italy), now gathering with the international faculty members in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

This year new topics of discussion have been identified with special emphasis on latest findings in melanoma research and advances: Diagnosis and new procedure, Molecular advances and combination therapies, News in immunotherapy, Tumor microenvironment and biomarkers. On December 8th the experts will share a round table focusing on immunoscore technique and, subsequently, a second round table on Regulatory Issues on Melanoma Drugs.

GENERAL INFORMATION



CME PROVIDER AND ORGANISING AGENCY:

3P Solution Srl
Via Marradi 3, 20123 Milan
Phone +39 02 36631574
Fax +39 02 89098927
Cell. +39 3496485434
www.3psolution.it
info@3psolution.it
info@melanomabridge.org

OFFICIAL LANGUAGE:

The official language is English

REGISTRATION:

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific program
- CME credits
- coffee breaks and lunches from December 6th to 8th
- congress bag

Participants are kindly requested to inform us about any dietary habit (*i.e.* food allergies/intolerances, vegetarian or vegan habits).

Please register at 3P Solution desk (cash or credit card accepted).

GENERAL INFORMATION



CONGRESS VENUE:

Royal Continental Hotel

Via Partenope, 38-44

80121 - Naples

Phone +39 081 245 2068

www.royalgroup.it/royalcontinental/



E.C.M.

Commissione Nazionale Formazione Continua



CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

Melanoma Bridge is accredited by the Italian Ministry of Health for 20 CME credits. The specialties eligible for CME credits are: Medical Doctors, Pharmacists, Biologists, and Nurses.

In order to receive credits, participants must:

1. Attend all the accredited sessions;
2. Complete the assessment test at the end of the congress (a grade of 75% must be obtained to receive CME credit);
3. Complete the evaluation questions at the end of the congress.

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.



Melanoma Bridge



SCIENTIFIC PROGRAM

SCIENTIFIC PROGRAM

DECEMBER 5TH 2013

- 17.00 Opening Ceremony**
Nicola Mozzillo, Francesco M. Marincola
- 17.10 In ricordo di un amico: Natale Cascinelli**
In memory of a friend: Natale Cascinelli
Nicola Mozzillo , Paolo A. Ascierto
- 17.30 Stato dell'Arte e nuove prospettive**
State of the Art and new perspectives
Paolo A. Ascierto
- 17.45 L'impegno della Fondazione Melanoma**
The commitment of the Fondazione Melanoma
Antonio Brancaccio (*Responsabile Area Pazienti, Fondazione Melanoma*)
- 18.00 Melanoma and the role of patient advocacy**
Valerie Guild
- 18.30 Presentazione attività 2014 Fondazione Melanoma**
Presentation of the Fondazione Melanoma activities 2014
- 18.45 Award Cerimony**

È prevista la traduzione simultanea
Simultaneous translation will be provided

* Invited speaker

** Not included in the CME accredited program

SCIENTIFIC PROGRAM

DECEMBER 6TH 2013

DIAGNOSIS AND NEW PROCEDURES

Chair: Jeffrey Gershenwald, Nicola Mozzillo

- 9.30 The role of melanoma genetic testing in prevention and early detection
Sancy Leachman
- 9.55 How should melanoma patients be followed-up?
Clause Garbe
- 10.20 Clinically important data from gene microarray studies of melanocytic lesions
Alistair Cochran
- 10.45 AJCC classification, the Melanoma Cancer Genome Atlas Program (TCGA),
and beyond: Integrated models in the molecular era
Jeffrey Gershenwald
- 11.10 Break
- 11.25 Combination therapies and Surgery in the treatment of metastatic melanoma
Nicola Mozzilo
- 11.50 Diagnosis and new procedures: innovation and sustainability
Alessandro Testori
- 12.15 Are there systemic benefits to local and regional therapy of metastases
in melanoma?
Mark Faries
- 12.40 Discussion on the best abstracts on diagnosis and new procedures
Jeffrey Gershenwald, Nicola Mozzillo
- Revealing cancer initiating cells in metastatic melanomas by harnessing
the host's anti tumor humoral immune mechanisms presented by
Beatrix Kotlan
- Activation of the ErbB3-AKT axis promotes melanoma cell survival and
proliferation in response to RAF/MEK inhibition presented by
Luigi Fattore
- 13.00 Lunch & Poster Session **

** Not included in the CME accredited program

SCIENTIFIC PROGRAM

DECEMBER 6TH 2013

MOLECULAR ADVANCES AND COMBINATION THERAPIES

Chair: Paolo A. Ascierto, Giuseppe Palmieri

- 14.00 Melanoma next-generation sequencing, biological significance and clinical applications
Ruth Halaban
- 14.25 Biological and clinical implications of cell signaling in melanoma
Richard Marais
- 14.50 Targeting apoptosis to enhance the effectiveness of BRAF-directed therapy in melanoma
Ryan Sullivan
- 15.15 CSF-1 and Erk inhibitors for melanoma
Antoni Ribas
- 15.40 Break
- 16.05 Recent advances in melanoma combination therapy
Igor Puzanov
- 16.30 Combination Therapies: The Solution to Drug Resistance?
James Larkin
- 16.55 LGX818 + MEK162 combination therapy of melanoma and beyond BRAFi/MEKi
Richard Kefford
- 17.20 Discussion on the best abstracts on Molecular advances and Combination Therapies
Paolo A. Ascierto, Giuseppe Palmieri

Assessment of germline and somatic alterations in main candidate genes among patients with multiple primary melanoma presented by Maria Colombino

Regulation of melanoma initiating cells by Hedgehog signaling and SOX2, presented by Barbara Stecca

SCIENTIFIC PROGRAM

DECEMBER 6TH 2013

Combination therapy with ipilimumab and electrochemotherapy: preliminary efficacy results and correlation with immunological parameters presented by Ester Simenone

Efficacy of Radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg presented by Antonio M. Grimaldi

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7) presented by Igor Puzanov

18.20 Closing remarks and summing up for the next day

SCIENTIFIC PROGRAM

DECEMBER 7TH 2013

NEWS IN IMMUNOTHERAPY

Chair: Michele Maio, Giuseppe Masucci

- 9.20 Award lecture of Fondazione Melanoma: New Approaches to Adjuvant Therapy
John M. Kirkwood
- 9.50 Escape mechanisms in melanoma
Soldano Ferrone
- 10.15 Understand variants contribute to immune responsiveness
Ena Wang
- 10.40 Distinct strategies of melanoma to evade immune surveillance and induce resistance to targeted therapies
Barbara Seliger
- 11.05 Break
- 11.20 Targeting the Tim-3 pathway in cancer
Ana Carrizosa Anderson
- 11.45 Combinations of Immunotherapy
F. Stephen Hodi
- 12.10 Recent Advances in Adoptive T Cell Therapies
David Stroncek
- 12:35 Discussion on the best abstracts on News in immunotherapy
Michele Maio, Giuseppe Masucci

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab presented by Michael A. Postow

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production presented by Giusy Gentilcore

SCIENTIFIC PROGRAM

DECEMBER 7TH 2013

Harnessing host innate immunity may combat acquired resistance to BRAFi presented by Francesco Colucci

Regulated intratumoral expression of IL-12 as a basis for combination therapy in melanoma presented by Jonathan Lewis

13.30 Lunch & Poster Session**

*** Not included in the CME accredited program*

SCIENTIFIC PROGRAM

DECEMBER 7TH 2013

TUMOR MICROENVIRONMENT AND BIOMARKERS

Chair: Magdalena Thurin, Gennaro Ciliberto

- 14.30 Signature genes and molecular biomarkers of melanoma predisposition to prometastatic effects of inflammation
Fernando Vidal-Vanaclocha
- 14.55 Immunotherapies based on CD137
Ignacio Melero
- 15.20 Inflammation in tumor progression
Alberto Mantovani
- 15.45 Immunoprofiling responders to immunotherapy
Carlo Bifulco
- 16.10 Break
- 16.25 New candidate biomarkers for cytokine and ipilimumab activity
Alexander Eggermont
- 16.50 Mechanisms mediating a T cell-inflamed versus non-inflamed melanoma tumor microenvironment
Thomas F. Gajewski
- 17.15 Immunological consequences of BRAF inhibitor treatment
Bastian Schilling
- 17.35 Immune gene expression patterns in primary melanoma tumors predict clinical outcomes
Yvonne Saenger
- 17.50 Discussion on the best abstracts on Tumor Microenvironment and Biomarkers
Magdalena Thurin, Gennaro Ciliberto

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma presented by Antoni Ribas

SCIENTIFIC PROGRAM

DECEMBER 7TH 2013

Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification presented by Rachael Hawtin

18.30 Closing remarks and summing up for the next day

SCIENTIFIC PROGRAM

DECEMBER 8TH 2013

WORLD-WIDE IMMUNOSCORE TASK FORCE: AN UPDATE

Francesco M. Marincola, Paolo A. Ascierto

9.00 Immunoscoring participants round table on recent advances

The importance of the Immunoscoring for cancer classification, and give an update on the French cohort from the worldwide Immunoscoring consortium

Jerome Galon

The Medical Need for an Immune Scoring/Profiling for Melanoma and Other Cancer Patients

Paolo A. Ascierto

Gene expression profiling versus IHC to identify an active T cell-infiltrated melanoma microenvironment

Thomas Gajewski

Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy

Andrea Anichini

Update on definien's Immunoscoring module/plugin and on the status of Portland's Immunoscoring consortium's cohort

Carlo Bifulco

Using NanoString technology to develop strategies to enhance the immunoscoring
Yvonne Saenger

Update on the status of the project in the middle-eastern countries

Lotfi Chouchane

HLA-G identification and genus dependent HLA_A2 prognostic relevance in coloncancer cases participating to the immunoscoring project

Giuseppe Masucci

11.15 Break

SCIENTIFIC PROGRAM

DECEMBER 8TH 2013

REGULATORY SESSION

Pier Luigi Canonico, Sabino De Placido*

11.30 Round Table on Regulatory issues of Melanoma drugs

Paolo A. Ascierto

(Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy)

Antonio Brancaccio

(Fondazione Melanoma)

European Cancer Patients Coalition: an innovative approach to face melanoma

Francesco De Lorenzo *(President of European Cancer Patient Coalition, ECPC)*

New drugs for melanoma: are they sustainable?

Luca Pani *(General Director of the Italian Medicines Agency, AIFA)*

Carmine Pinto

(President Elect of the Italian Association of Medical Oncology, AIOM)

Paola Queirolo*

(President Elect of the Italian Melanoma Intergroup)

Carlo Riccardo Rossi*

(President of the Italian Melanoma Intergroup)

Francesco Rossi

(President of the Italian Society of Pharmacology, SIF)

13:30 Closing remarks

13:45 CME test

POSTER SESSION

DECEMBER 6TH / 7TH 2013 Lunch Area First Floor

DIAGNOSIS AND NEW PROCEDURES

1. Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma
Ugo Marone *et al.*
2. A novel approach to target metastases of melanoma cells in an organ-selective manner
Donna L. Senger *et al.*
3. UV exposure and melanoma prognostic factors: results from Clinical National Melanoma Registry
Maurizio Montella *et al.*
4. Psychological features in lower risk melanoma: an analysis on 204 patients
Simone Ribero *et al.*

POSTER SESSION

DECEMBER 6TH / 7TH 2013 Lunch Area First Floor

MOLECULAR ADVANCES AND COMBINATION THERAPIES

5. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: Preliminary results
Richard Kefford *et al.*
6. In vivo targeting of cutaneous melanoma using an MSH-engineered human protein cage bearing fluorophore and MRI tracers
Cristina Maria Failla *et al.*
7. Barasertib: a novel approach for the treatment of metastatic melanoma
Amalia Azzariti *et al.*
8. Overall survival of patients with chemotherapy-naïve advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
Reinhard Dummer *et al.*
9. The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
Gabriella Guida *et al.*

POSTER SESSION

DECEMBER 6TH / 7TH 2013 Lunch Area First Floor

TUMOR MICROENVIRONMENT AND BIOMARKERS

10. Enrichment of KIR+CD57+ highly cytotoxic NK cells in sentinel lymph nodes of melanoma patients
Ennio Carbone *et al.*
11. MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIllimumab
Carlo Bifulco *et al.*
12. hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?
Paola Nisticò *et al.*
13. Natural immunomodulator preimplantation factor (PIF) affects cancer growth in malignant melanomas
Beatrix Kotlan *et al.*

2013

Melanoma
Bridge



Melanoma
Bridge

Melanoma Bridge



2013

**PRESIDENT
SCIENTIFIC BOARD
FACULTY**

PRESIDENTS



Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy



Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar



Nicola Mozzillo

Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

SCIENTIFIC BOARD

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Lotfi Chouchane

Assistant Dean for Basic Science, Professor of Genetic Medicine, Professor of Microbiology & Immunology, Weill Cornell Medical College, Qatar

Gennaro Ciliberto

Scientific Director of the National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Clause Garbe

University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

John M. Kirkwood

Usher Professor of Medicine, Dermatology, and Translational Science University of Pittsburgh School of Medicine Director, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute

Alberto Mantovani

Scientific Director of Istituto Clinico Humanitas, Milan, Italy

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci

Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero

Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo

Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Giuseppe Palmieri

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

SCIENTIFIC BOARD

Antoni Ribas

Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

David Stroncek

Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Walter Urba

Director cancer research, Earle A. Chiles Research Institute, Providence Cancer Center, Providence, Oregon

Fernando Vidal-Vanaclocha

Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang

Acting Section Head of Infectious Disease and Immunogenetics Section (IDIS); Director of Molecular Science, Department of Transfusion Medicine, CC; Associated director of Center for Human Immunology, NIH, Maryland

FACULTY

Paolo A. Ascierto

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Tumori Fondazione Pascale, Naples, Italy

Carlo Bifulco

Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Pier Luigi Canonico

Department of Scienze del Farmaco, University of Piemonte Orientale, Novara, Italy

Ana Carizzosa Anderson

Assistant Professor at Kuchroo Laboratory, Center for Neurologic Disease Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Lotfi Chouchane

Assistant Dean for Basic Science, Professor of Genetic Medicine, Professor of Microbiology & Immunology, Weill Cornell Medical College, Qatar

Gennaro Ciliberto

Scientific Director of the National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Alistair Cochran

Distinguished Professor of Pathology and Laboratory Medicine, UCLA, California

Francesco De Lorenzo

President of Italian Federation of Volunteer-based Cancer Organizations, FAVO

Sabino De Placido*

Professor of Medical Oncology, University of Naples, Italy

Alexander Eggermont

Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

Mark Faries

Department of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California

Soldano Ferrone

University of Pittsburgh, Department of Pathology and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

FACULTY

Thomas F. Gajewski

Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois

Jerome Galon

Research Director at INSERM (National Institute of Health and Medical Research), Paris, France

Clause Garbe

University Professor of Dermatology, Head, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen (Stuttgart), Germany

Jeffrey E. Gershenwald

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas

Ruth Halaban

Director, Yale SPORE in Skin Cancer, Yale University School of Medicine, Department of Dermatology, New Haven, Connecticut

F. Stephen Hodi

Dana-Farber Cancer Institute, Boston, Massachusetts

Richard Kefford

Professor of Medicine and Director of the Westmead Institute for Cancer Research and Consultant Medical Oncologist to the Sydney Melanoma Unit and the NSW Breast Cancer Institute, Sydney, Australia

John M. Kirkwood

Usher Professor of Medicine, Dermatology, and Translational Science University of Pittsburgh School of Medicine Director, Melanoma and Skin Cancer Program University of Pittsburgh Cancer Institute

James Larkin

Department of Medicine, The Royal Marsden Hospital, London, UK

Sancy Leachman

Professor and Chair, Department of Dermatology, Oregon Health & Sciences University

Michele Maio

U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria Senese, Siena, Italy

Alberto Mantovani

Scientific Director of Istituto Clinico Humanitas, Milan, Italy

FACULTY

Richard Marais

Director, Paterson Institute for Cancer Research, Manchester, United Kingdom

Francesco M. Marincola

Chief Research Officer, Sidra Medical and Research Centre, Doha, Qatar

Giuseppe Masucci

Professor, Department of Oncology-Pathology, and KcRN, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Ignacio Melero

Professor of Immunology and Consultant, CIMA, CUN and Medical School, University of Navarra, Pamplona, Spain

Nicola Mozzillo

Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Giuseppe Palmieri

Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy

Luca Pani

General Director, Italian Medicines Agency - AIFA

Carmine Pinto

President Elect of Associazione Italiana di Oncologia Medica, AIOM

Igor Puzanov

Associate Professor of Medicine, Clinical Director, Renal Cancer/Melanoma, Vanderbilt University, Nashville, Tennessee

Antoni Ribas

Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

Yvonne Saenger

Departments of Dermatology, Mount Sinai School of Medicine, New York

Bastian Schilling

Department of Dermatology, University Hospital Essen, Essen, Germany

FACULTY

Barbara Seliger

Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Saale, Germany

David Stroncek

Chief, Cell Processing Section, Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland

Ryan Sullivan

Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Alessandro Testori

Melanoma and muscle-cutaneous sarcomas Division, Istituto Europeo di Oncologia, Milan, Italy

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Fernando Vidal-Vanaclocha

Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang

Acting Section Head of Infectious Disease and Immunogenetics Section (IDIS); Director of Molecular Science, Department of Transfusion Medicine, CC; Associated director of Center for Human Immunology, NIH, Maryland

NOTES



This CME event has been sponsored by an *unrestricted grant* from:



Bristol-Myers Squibb



NOVARTIS



MSD



Roche



VENTANA®



IMMUDEx